Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
- Age-Related Macular Degeneration
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- University of Wisconsin, Madison
- Enrolment target
- 1,000
- Started
- 12 May 2025
- Main results due (estimated)
- June 2027
- Study ends (estimated)
- June 2027
- Observational model
- Cohort
- Time perspective
- Prospective
- Sites
- 15 · 2 in India
- First posted
- 11 April 2025
- Registry updated
- 30 October 2026
Can you take part?
- Aged 50 years and over.
- Open to any sex.
- Healthy volunteers can take part.
- Who they are looking for: Approximately 1000 participants from up to 25 sites in the United States, Europe, Asia, South America, Africa, and Australia will be enrolled and balanced by age, sex, and AMD level (worse eye selected as study eye). Every region listed above may not be represented and additional regions/countries not listed above may be included.
Age groups: adult, older adult. Sampling: non probability sample.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form * Willing to comply with all study procedures and sign the Informed Consent Form (ICF) * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center. Exclusion Criteria: * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed. * Unable to acquire adequate quality images, as evaluated by the Central Reading Center * Severe vision loss requiring urgent surgery * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study * Unwilling to sign informed consent form * Currently or previously enrolled in an interventional AMD clinical trial
What this study is about
In the sponsor’s own words, from the registry.
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Read the detailed description
Age-related macular degeneration (AMD) is a leading cause of blindness in the world. The early and intermediate stages of AMD progress to late stage resulting in vision loss due to either geographic atrophy or neovascular AMD. Preventive measures to reduce treatment burden and prevent blindness are important. While there are no approved therapies for early disease, active research is underway. However, advancing therapeutic trials for AMD prevention remains challenging due to the lack of primary care involvement in early-stage AMD diagnosis.
A clear need exists for a reliable screening tool, deployable in optometry or primary care facilities to identify those with an early stage of disease. While an Artificial Intelligence (AI) based screening tool would be an ideal solution, there are obstacles to its prospective validation due to difficulty in enrolling sufficient cases in a screening environment. A key step towards promoting this field lies in collecting a diverse dataset of multimodal imaging and providing a reference standard level 1 classification from a wide array of patients with AMD. Having such a benchmark dataset available for research purposes will empower the development and validation of AI models for AMD. This data can serve as the much-sought pathway to the rapid development of screening models, facilitating the referral of patients with the appropriate disease spectrum, and ultimately leading to the prevention of late AMD.
This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.
Study procedures include:
* Patient history: demographics (age, sex, ethnicity, race), smoking history, family history of AMD * Physical exam: height and weight * Snellen best-corrected visual acuity (BCVA) * AMD classification (Beckman scale)
Eligible participants will undergo one retinal imaging session of both eyes for the following:
* Single field stereo color fundus photography (cFP) - pre and post dilation * Macular spectral domain-optical coherence tomography (SD-OCT)
Due to the need for diversity in the dataset, sites need to represent a wide array of geographical locations. In addition, balancing will be done on enrolled participants with or without AMD including age, sex, and AMD level (worse eye selected as study eye).
Keywords: screening · artificial intelligence · AI
What participants receive
AMD Benchmark Imaging Dataset Cohort
Study Procedures Include: * Patient history: demographics (age, sex, ethnicity, race), smoking history, family history of AMD * Physical exam: height and weight * Snellen best-corrected visual acuity (BCVA) * AMD classification (Beckman scale)
Other: Retinal Imaging
Interventions
Retinal ImagingOther
Also known as Single field stereo color fundus photography, Macular spectral domain-optical coherence tomography
Eligible participants will undergo one retinal imaging session of both eyes for the following: * Single field stereo color fundus photography (cFP) - pre and post dilation * Macular spectral domain-optical coherence tomography (SD-OCT)
What the study measures
Primary outcomes
AMD Classification by Participant Count
A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by classifying AMD status. The goal is to have: * 20% participants with no AMD * 30% participants with Early AMD * 30% participants with Intermediate AMD * 10% participants with Geographic Atrophy (GA) * 10% participants with Neovascular age-related macular degeneration (nAMD)
Time frame: up to 18 months
Geographic Location by Participant Count
A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by geographic location. 1000 participants from up to 25 global sites will be included.
Time frame: up to 18 months
Who is running it
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- Other
- Responsible party
- The sponsor
- Organisation
- University of Wisconsin, Madison
- Data monitoring committee
- No
- US FDA-regulated drug
- No
- US FDA-regulated device
- No
- Sponsor's study ID
- 2025-0059
- Other IDs
- Protocol Version 3/14/2025, A536070
Amitha Domalpally, MD, PhD
Principal investigator
UW School of Medicine and Public Health
Study sites(15)
Sankara Nethralaya, Medical Research Foundation
Chennai, Tamil Nadu, India
Recruiting
Aravind Eye Hospital
Chennai, Tamil Nadu, India
Recruiting
Emory University
Atlanta, Georgia, United States
Recruiting
- Afif Martini404-778-5815mohamed.afif.martini@emory.edu
Bergstrom Eye Research LLC
Fargo, North Dakota, United States
Recruiting
Erie Retina Research
Erie, Pennsylvania, United States
Recruiting
Retina Foundation of the Southwest
Dallas, Texas, United States
Recruiting
Valley Retina Institute
McAllen, Texas, United States
Recruiting
Retina Consultants of Texas (Houston)
The Woodlands, Texas, United States
Recruiting
University of Utah - John A. Moran Eye Center
Salt Lake City, Utah, United States
Recruiting
University Station Eye Care Clinic
Madison, Wisconsin, United States
Recruiting
Adelaide Eye and Retina Centre
Adelaide, Australia
Recruiting
- Kerin Haywood+61 8 8212 3022khaywood@adelaideeye.com.au
Aga Khan University
Karachi, Pakistan
Recruiting
Kim Eye Hospital
Seoul, South Korea
Recruiting
- GuHeui Jo+82 1577-2639fm@kimeye.com
Charles Research Center
Buenos Aires, Argentina
Not yet recruiting
University of Bonn - Department of Ophthalmology
Bonn, Germany
Not yet recruiting
Showing 15 of 15 sites. 13 recruiting, 2 not recruiting and 0 cancelled; 2 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- No
Source: ClinicalTrials.gov record NCT06924021, status verified March 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.